RNA的N6-甲基腺嘌呤甲基化在肿瘤发生中作用的研究进展

doi:10.3969/j.issn.1004-616x.2021.01.016

癌变·畸变·突变 ›› 2021, Vol. 33 ›› Issue (1): 77-80.doi: 10.3969/j.issn.1004-616x.2021.01.016

• 综述 • 上一篇

RNA的N⁶-甲基腺嘌呤甲基化在肿瘤发生中作用的研究进展

王一帆¹, 许铭炎², 邓小玲¹

1. 厦门大学医学院基础医学部, 福建厦门 361102;
2. 厦门医学院附属口腔医院重点实验室, 福建厦门 361009

收稿日期:2020-07-17 修回日期:2020-12-02 出版日期:2021-01-30 发布日期:2021-02-06
通讯作者: 许铭炎,E-mail:mingyan_xu@qq.com;邓小玲,E-mail:xiaolingdeng@xmu.edu.cn E-mail:mingyan_xu@qq.com；xiaolingdeng@xmu.edu.cn
作者简介:王一帆,E-mail:wyf14220132@163.com。
基金资助:
国家自然科学基金（81671001，82071128）；厦门市“重要重大疾病联合攻关计划”项目（3502z20179052）；厦门医学院自然科学基金（k2016-39）

Received:2020-07-17 Revised:2020-12-02 Online:2021-01-30 Published:2021-02-06

摘要/Abstract

摘要： RNA的N⁶-甲基腺嘌呤（m⁶A）甲基化是RNA修饰的最主要形式，参与m⁶A甲基化与去甲基化过程的酶分为3类：甲基转移酶，去甲基酶和m⁶A结合蛋白。这3类调控m⁶A的蛋白在RNA的加工代谢以及正常生理功能中发挥重要的调节作用，并且通过调节RNA的转录、剪接、加工、翻译和衰变等过程参与多种恶性肿瘤的发生和转移。近年来随着m⁶A检测技术的发展，m⁶A甲基化在恶性肿瘤病理进程中的作用研究逐渐成为热点。本文就有关m⁶A甲基化修饰影响肿瘤病程的表观遗传学机制进行综述，旨在为以m⁶A甲基化为靶点的肿瘤治疗策略提供新思路。

关键词: RNA, 表观遗传学, m⁶A甲基化, 肿瘤

中图分类号:

R741

王一帆, 许铭炎, 邓小玲. RNA的N⁶-甲基腺嘌呤甲基化在肿瘤发生中作用的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 77-80.

参考文献

[1] DESROSIERS R, FRIDERICI K, ROTTMAN F. Identification of methylated nucleosides in messenger RNA from novikoff hepatoma cells[J]. PNAS, 1974, 71(10):3971-3975.
[2] JIA G F, FU Y, ZHAO X, et al. N⁶-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol, 2011, 7(12):885-887.
[3] MEYER K D, SALETORE Y, ZUMBO P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons[J]. Cell, 2012, 149(7):1635-1646.
[4] EDUPUGANTI R R, GEIGER S, LINDEBOOM R G H, et al. N⁶methyladenosine (m⁶A) recruits and repels proteins to regulate mRNA homeostasis[J]. Nat Struct Mol Biol, 2017, 24(10):870-878.
[5] LIU N, DAI Q, ZHENG G Q, et al. N⁶-methyladenosinedependent RNA structural switches regulate RNA-protein interactions[J]. Nature, 2015, 518(7540):560-564.
[6] XIAO W, ADHIKARI S, DAHAL U, et al. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing[J]. Mol Cell, 2016, 61(4):507-519.
[7] ROUNDTREE I A, LUO G Z, ZHANG Z, et al. YTHDC1 mediates nuclear export of N⁶-methyladenosine methylated mRNAs[J/OL]. eLife, 2017, 6:e31311. DOI:10.7554/eLife. 31311.
[8] DU H, ZHAO Y, HE J Q, et al. YTHDF₂ destabilizes m⁶Acontaining RNA through direct recruitment of the CCR4-NOT deadenylase complex[J]. Nat Commun, 2016, 7:12626.
[9] WANG X, LU Z K, GOMEZ A, et al. N⁶-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014, 505(7481):117120.
[10] PATIL D P, CHEN C K, PICKERING B F, et al. m⁶A RNA methylation promotes XIST-mediated transcriptional repression[J]. Nature, 2016, 537(7620):369-373.
[11] ZHAO X, YANG Y, SUN B F, et al. FTO-dependent demethylation of N⁶-methyladenosine regulates mRNA splicing and is required for adipogenesis[J]. Cell Res, 2014, 24(12):1403-1419.
[12] JAIN D, PUNO MR, MEYDAN C, et al. ketu mutant mice uncover an essential meiotic function for the ancient RNA helicase YTHDC2[J/OL]. eLife 2018, 7:e30919. DOI:10.7554/eLife.30919.
[13] ZHANG C X, CHEN Y S, SUN B F, et al. m⁶A modulates haematopoietic stem and progenitor cell specification[J]. Nature, 2017, 549(7671):273-276.
[14] BARBIERI I, TZELEPIS K, PANDOLFINI L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m⁶Adependent translation control[J]. Nature, 2017, 552(7683):126-131.
[15] BANSAL H, YIHUA Q, IYER S P, et al. WTAP is a novel oncogenic protein in acute myeloid leukemia[J]. Leukemia, 2014, 28(5):11711174.
[16] SU R, LI Z J, WENG H Y, et al. Fto plays an oncogenic role in acute myeloid leukemia as a N⁶-methyladenosine RNA demethylase[J]. Blood, 2016, 128(22):2706.
[17] MA J Z, YANG F, ZHOU C C, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N⁶methyladenosine-dependent primary microRNA processing[J]. Hepatology, 2017, 65(2):529-543.
[18] LI J, ZHU L, SHI Y, et al. m⁶A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation[J]. Am J Transl Res, 2019, 11(9):6084-6092.
[19] RONG Z X, LI Z, HE J J, et al. Downregulation of fat mass and obesity associated (FTO) promotes the progression of intrahepatic cholangiocarcinoma[J]. Front Oncol, 2019, 9:369..
[20] YANG Z, LI J, FENG G X, et al. MicroRNA145 Modulates N⁶methyladenosine levels by targeting the 3'untranslated mRNA region of the N⁶methyladenosine binding YTH domain family 2 protein[J]. J Biol Chem, 2017, 292(9):3614-3623.
[21] ZHANG C Z, HUANG S Z, ZHUANG H K, et al. YTHDF₂ promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m⁶A RNA methylation[J]. Oncogene, 2020, 39(23):4507-4518.
[22] CUI Q, SHI H L, YE P, et al. M ⁶A RNA methylation regulates the selfrenewal and tumorigenesis of glioblastoma stem cells[J]. Cell Rep, 2017, 18(11):2622-2634.
[23] XU C Y, YUAN B J, HE T, et al. Prognostic values of YTHDF₁ regulated negatively by mir-3436 in Glioma[J]. J Cell Mol Med, 2020, 24(13):7538-7549.
[24] ZHANG C Z, ZHI W I, LU H Q, et al. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF^217- and ALKBH⁵-mediated modulation of RNA methylation in breast cancer cells[J]. Oncotarget, 2016, 7(40):64527-64542.
[25] ZHANG C Z, SAMANTA D, LU H Q, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH₅-mediated m⁶A-demethylation of NANOG mRNA[J]. PNAS, 2016, 113(14):E2047-E2056..
[26] VAN TRAN N, ERNST F G M, HAWLEY B R, et al. The human 18S rRNA m⁶A methyltransferase METTL5 is stabilized by TRMT112[J]. Nucleic Acids Res, 2019, 47(15):7719-7733.
[27] HUANG Y, SU R, SHENG Y, et al. Smallmolecule targeting of oncogenic FTO demethylase in acute myeloid leukemia[J]. Cancer Cell, 2019, 35(4):677-691.
[28] DU K Z, ZHANG L B, LEE T, et al. m⁶A RNA methylation controls neural development and is involved in human diseases[J]. Mol Neurobiol, 2019, 56(3):1596-1606.

RNA的N⁶-甲基腺嘌呤甲基化在肿瘤发生中作用的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李昕苇, 王全凯, 马顺鹏, 王苗, 乌瀚宝栎尔, 顾轶婷, 康同影, 许建宁. 甲基丙烯酸环氧丙酯诱导16HBE细胞恶性转化过程中LncRNA表达特征分析及ceRNA调控网络预测[J]. 癌变·畸变·突变, 2022, 34(1): 1-6.
[2]	祝欣萍, 贾迪, 林少辉, 刘晨, 李婧铱, 赵炜明. 新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用[J]. 癌变·畸变·突变, 2022, 34(1): 47-52,66.
[3]	问天娇, 李思颖, 郑颖, 崔京霞. 脂质体技术在铂类药物抗肿瘤研究中的应用[J]. 癌变·畸变·突变, 2022, 34(1): 72-74.
[4]	刘宁, 梁兰兰, 李淑芳, 沈祥春, 梁冰. 氧化苦参碱对小鼠肉瘤和肝癌的体内外抗肿瘤作用[J]. 癌变·畸变·突变, 2021, 33(6): 426-429,434.
[5]	王蕊, 王珩, 吴娟, 纪晓坤, 郭晓, 马阳, 杜芸. 全自动DNA图像分析系统在胰腺恶性肿瘤诊断中的价值[J]. 癌变·畸变·突变, 2021, 33(6): 451-454.
[6]	张宗敏. 甲状腺微小癌是否需要手术[J]. 癌变·畸变·突变, 2021, 33(5): 325-326.
[7]	孙惠昕, 张茂祥, 王婉莹, 贾海晗, 宋冰冰. 2013—2017年黑龙江省肿瘤登记地区前列腺癌发病死亡情况及趋势分析[J]. 癌变·畸变·突变, 2021, 33(5): 345-348.
[8]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[9]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[10]	常晨, 杨荔艳, 蔡洪庆, 苑青, 郝佳洁, 王明荣. 食管鳞癌中SERPINE1 mRNA的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(4): 245-249.
[11]	程书钧. 衰老和恶性肿瘤──防治的思考[J]. 癌变·畸变·突变, 2021, 33(3): 161-162.
[12]	罗娇, 张坤驰, 周莉. 三阴性乳腺癌细胞系MDA-MB-231与其脑转移细胞系中microRNA差异表达分析[J]. 癌变·畸变·突变, 2021, 33(3): 218-224.
[13]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[14]	张玉领, 陈培. 环状RNA在食管癌中的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 241-245.
[15]	田薇, 方延, 吴晗恬, 吉布强, 夏昭林. 长链非编码RNA与mRNA在急性髓性白血病中的异常表达及其功能初探[J]. 癌变·畸变·突变, 2021, 33(2): 110-115.